We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Enzo Biochem Launches Proprietary Test for Detection of Coronavirus SARS-CoV-2 IgG Antibody

By LabMedica International staff writers
Posted on 21 May 2020
Enzo Biochem (New York, NY, USA) has launched a SARS-CoV-2 IgG ELISA assay kit for serological detection of IgG antibodies against the novel coronavirus under the FDA’s Emergency Use Authorization (EUA) authority as both products and services.

The assay permits the qualitative detection of Immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human serum and is designed to provide accurate results in a clinical laboratory setting with low- to high-throughput processing of specimens. More...
The IgG Antibody Kit detects IgG antibodies specific for SARS-CoV-2 to identify individuals previously exposed to and infected by the coronavirus, even if they have never displayed symptoms. In a clinical study, the performance of the SARS-CoV-2 ELISA kit was compared with a molecular diagnosis (PCR) using serum samples from approximately 150 individuals. Positive percent agreement (PPA) and negative percent agreement (NPA) with a comparator PCR observed 96.5% specificity and 100% sensitivity.

Enzo’s high-throughput kit for IgG antibody utilizes a routine blood collection at a lab’s patient service center, a doctor’s office, or a hospital. The sample is then sent to the clinical laboratory for processing and analysis. This workflow permits scalable testing to be performed under controlled conditions to deliver accurate and sensitive results. These new serological tests, which are built on Enzo’s proprietary ELISA platform, work with serum specimens and are formatted for both manual test processing situations as well as automated, high-throughput clinical workflows. Enzo’s proprietary 96-well ELISA based technology is readily scalable to meet the needs of the clinical laboratory environment, while providing reliable and economical results. All kits are manufactured at Enzo’s GMP certified production facility.

“Serological testing will play a critical role in identifying individuals who are transitioning to post-infection status and have developed an immune response. While some competitor assays detect total immunoglobulin with no differentiation between immunoglobulin types, Enzo’s serological assays differentiate between these immunoglobulin types, thereby providing more information to clinicians for determining particular stages of infection,” said Dr. Elazar Rabbani, Enzo CEO. “As with the launch of Enzo’s molecular test for the detection of active coronavirus infection, our serological assay test kit will be available for purchase by other clinical labs and is being used to perform serological testing at Enzo’s own CLIA-certified laboratory.”

Related Links:
Enzo Biochem


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nucleic Acid Isolation Kit
MagMAX™ Viral/Pathogen Ultra Nucleic Acid Isolation Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.